Mirum Pharmaceuticals (MIRM) Accounts Payables (2018 - 2026)

Mirum Pharmaceuticals has reported Accounts Payables for 9 years, with the latest figure at $59.4 million in Q1 2026.

• For the quarter ending Q1 2026, Accounts Payables rose 410.34% year-over-year to $59.4 million; the trailing twelve-month figure through Mar 2026 stood at $59.4 million (up 410.34% YoY), and the FY2025 full-year result was $9.6 million, down 34.23% from the prior year.
• Accounts Payables for Q1 2026 stood at $59.4 million, up from $9.6 million in the prior quarter.
• The five-year high for Accounts Payables was $59.4 million in Q1 2026, with the low at $4.9 million in Q1 2022.
• Average Accounts Payables over 5 years is $13.4 million, with a median of $9.8 million recorded in 2024.
• Year-over-year, Accounts Payables tumbled 34.23% in 2025 and surged 410.34% in 2026.
• Tracing MIRM's Accounts Payables over 5 years: stood at $8.7 million in 2022, then retreated by 14.66% to $7.4 million in 2023, then soared by 97.11% to $14.6 million in 2024, then plunged by 34.23% to $9.6 million in 2025, then surged by 517.84% to $59.4 million in 2026.
• The last three Accounts Payables figures came in at $59.4 million (Q1 2026), $9.6 million (Q4 2025), and $12.2 million (Q3 2025), per Business Quant data.

Peer Comparison